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To the Editor—We read with interest 
Groger and colleagues’ prospective study 
of Plasmodium ovale relapses in Gabon 
[1]. Their work is timely given non-
falciparum malaria’s increasing prom-
inence in Africa and the potential role 
of hypnozoite-induced relapses in this 
trend. Despite declines in Plasmodium 
falciparum transmission, molecular sur-
veys have shown a 6-fold increase in the 
odds of P.  ovale infection in Tanzania 
from 2010 to 2016 [2], and a similar trend 
in the Democratic Republic of Congo, 
where the species’ prevalence increased 
from 0.4 to 8.3% in national surveys con-
ducted in 2007 and 2013 [3, 4]. Successful 
interventions against P.  falciparum in 
Zanzibar [5] and Uganda [6] have not 
had the same effect on non-falciparum 
species. Clearly, P.  ovale is becoming an 
increasingly important malaria in Africa.
P. vivax studies have taught us that
characterizing malaria relapse epidemi-
ology is essential to elimination efforts yet 
supremely challenging. In this paper, the 
authors used real-time polymerase chain 
reaction (PCR) and Sanger sequencing to 
distinguish between P.  ovale curtisi and 
wallikeri species. They defined relapses 
in their cohort as homologous genotypes 
detected after at least 1 PCR-negative 
sample between episodes in the setting 
of adequate drug levels. In contrast to 
P. ovale curtisi, they found no P.  ovale
wallikeri relapses.
This finding is unexpected in the con-
text of studies of travelers returning from 
Africa. Across studies, P. ovale wallikeri-
infected travelers presented with pre-
sumptive relapse sooner after return 
to nonendemic areas than those with 
P. ovale curtisi, on the order of 1 versus
3  months, respectively (Table 1). What
could explain the difference?
Lessons learned from P.  vivax studies 
may explain this discordance. First, al-
though Groger et  al’s conservative def-
inition of relapse increases confidence 
in their calls, it also excludes relapses 
from heterologous hypnozoites. These 
hypnozoites account for the majority 
of relapses in Asia; they may arise from 
previously acquired infections and/or 
minority genotypes within a polyclonal 
infection, which are often missed by 
common genotyping approaches [7–9]. 
Thus, it is plausible that some or all of 
the 4 nonhomologous P.  ovale wallikeri 
reappearances that Groger et al detected 
represent heterologous hypnozoite-
induced relapse.
Second, acquired immunity likely plays 
a role in suppressing or masking relapses. 
Acquired strain-specific immunity during 
a febrile illness may prevent hypnozoites 
of the same genotype from achieving 
blood-stage breakthrough during a sub-
sequent relapse. If P.  ovale wallikeri is 
a frequently relapsing strain similar to 
Asian strains of P. vivax, early acquisition 
of immunity in endemic populations [10] 
could obscure the short-latency relapses 
observed in nonimmune travelers. This 
possibility provides an alternative expla-
nation for the differing P.  ovale wallikeri 
relapse frequencies reported by Groger 
et al compared to others.
Much remains unknown, as P. ovale in 
Africa has long existed in the shadow of 
P. falciparum. It is clear that additional re-
search is needed to build upon the work
by Groger et  al.[1] We commend the
authors on an intriguing first look into
P. ovale relapses in Africa and an epide-
miology that has yet to be defined.
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Table 1. Plasmodium ovale wallikeri and Plasmodium ovale curtisi Exhibit Different Relapse Latencies in Cases of Imported Malaria from Africa. 
Region Reporting Imported Cases P. ovale Cases (no.)
Median Latency Period (no. of days with IQR)
ReferenceP. ovale wallikeri P. ovale curtisi
United Kingdom (2003–2011) 134 41 (29–57) 86 (66–111) Nolder D, et al. BMJ Open 2013.
Spain (2005–2011) 35 10 (3–58) 95 (13–297) Rojo-Marcos G, et al. Mal J 2018.
China (2010–2017) 120 31 (14–99) 98 (8–199) Zhou R, et al. Sci Rep 2019. 
Abbreviation: IQR, interquartile range; P. ovale, Plasmodium ovale.
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